John Rothman, Ph.D.
Executive VP: Science & Operations
Dr. Rothman joined Advaxis Inc. in March of 2005 as Vice President of Clinical Development. He was involved in the development of the first interferon at Schering Inc. in a number of viral and oncologic diseases. At Schering he was responsible for the first clinical trial conducted in AIDS, which used interferon. Subsequently was director of a variety of clinical development sections at Hoffman LaRoche, and the Senior Director of Clinical Data Management at Roche. While at Roche his work in AIDS related Kaposi’s Sarcoma with interferon became the basis of the first filed BLA, for which he wrote the clinical section. From 2002 to 2005 Dr. Rothman was Vice President and Chief Technology Officer of Princeton Technology Partners
